Steven Cohen Immuno Gen, Inc. Transaction History

Point72 Asset Management, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $32.7 Million - $175 Million	8,712,142 New	8,712,142 $164 Million
Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $1.36 Million - $2.49 Million	-432,678 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.26 - $7.48 $1.84 Million - $3.24 Million	432,678 New	432,678 $2.06 Million
Q4 2021 Feb 14, 2022	SELL	$4.75 - $7.5 $3.39 Million - $5.36 Million	-714,700 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$5.02 - $6.59 $9.74 Million - $12.8 Million	-1,939,599 Reduced 73.07%	714,700 $4.05 Million
Q4 2018 Feb 14, 2019	SELL	$3.94 - $9.7 $13.9 Million - $34.1 Million	-3,518,466 Reduced 57.0%	2,654,299 $12.7 Million
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $35.4 Million - $46.4 Million	4,116,832 Added 200.24%	6,172,765 $58.5 Million
Q2 2018 Aug 14, 2018	BUY	$9.52 - $12.15 $19.6 Million - $25 Million	2,055,933 New	2,055,933 $20 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.